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Pathological high-frequency oscillations are a novel marker used to improve the delineation of epileptogenic tissue and, hence, the outcome of epilepsy surgery. Their practical
clinical utilization is curtailed by the inability to discriminate them from physiological
oscillations due to frequency overlap. Although it is well documented that pathological
HFOs are suppressed by antiepileptic drugs (AEDs), the effect of AEDs on normal HFOs
is not well known. In this experimental study, we have explored whether physiological
HFOs (sharp-wave ripples) of hippocampal origin respond to AED treatment. The results
show that application of a single dose of levetiracetam or lacosamide does not reduce
the rate of sharp-wave ripples. In addition, it seems that these new generation drugs do
not negatively affect the cellular and network mechanisms involved in sharp-wave ripple
generation, which may provide a plausible explanation for the absence of significant
negative effects on cognitive functions of these drugs, particularly on memory.
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HIGHLIGHTS
• Pathological high-frequency oscillations (pHFOs) represent electrographic biomarker of epileptogenic tissue.
• Current approaches are not able to distinguish pathological HFOs from physiological ones in
intracranial recordings.
• Antiepileptic drugs decrease the rate of pHFOs.
• Levetiracetam or lacosamide do not decrease the rate of sharp-wave ripples—a representative of
physiological HFOs.
• Pharmacological testing could be used to discriminate pathological and physiological HFOs.

INTRODUCTION
Pathological high-frequency oscillations (pHFOs) represent a new electrographic marker of epileptogenic tissue. Early after their discovery, pHFO analysis was introduced into the presurgical
evaluation to better delineate the resection margin and to improve the outcome of surgery. pHFOs
are classified according to their frequency into two main groups—ripples (80–250 Hz) and fast ripples (250–600 Hz) (1, 2). Although fast ripples are considered more specific for epileptogenic tissue
than ripples, both types of pHFO can localize the epileptogenic zone or seizure onset areas in humans
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who undergo exploration with invasive electrodes (1, 2). Several
studies have demonstrated the beneficial effect of complete resection of the pHFO generating areas on surgical outcome (3–5).
The practical utilization of pHFOs in presurgical evaluation is
substantially hindered by the inability to differentiate them from
physiological high-frequency oscillations, such as hippocampal
sharp-wave ripples (SWRs) as they display substantial frequency
overlap (2, 6, 7). Currently, we do not have any effective tools,
which can reliably discriminate between them. Identification of
an approach to reliably discriminate between normal and pathological HFOs is a complex, but essential, issue to address if the
properties of pHFOs are to be fully utilized in clinical practice.
One of the features of pHFOs is their responsiveness to
antiepileptic drugs (AEDs). In the chronic pilocarpine model
of temporal lobe epilepsy, pHFOs and seizure rate decrease
after treatment with levetiracetam (8) or lacosamide (9). In
humans, withdrawal of AEDs is associated with increased rate
of pHFOs (10). A pharmacological test using AEDs could be a
plausible strategy to discriminate physiological oscillations from
pathological ones, providing rate of physiological HFOs is not
decreased by AEDs.
In this proof-of-principle study, we explored the impact of a
single dose of lacosamide or levetiracetam on the rate of SWRs—a
hippocampal representative of physiological HFOs (11). SWRs
play a crucial role in the process of coordinated memory reactivation and formation of long-term memory (12). We have tested
the hypothesis that the application of a single therapeutic dose of
levetiracetam or lacosamide does not affect SWR rate.

Each animal received sequential intraperitoneal injections of
levetiracetam (Keppra®, UCB, S.A., Brussels, Belgium), saline
(control solution) of equal volume, lacosamide (Vimpat®,
UCB, S.A., Brussels, Belgium), and saline of equal volume.
Additionally, three of the animals received diazepam (Apaurin®,
Krka, d. d., Novo Mesto, Slovenia) and saline of equal volume.

MATERIALS AND METHODS
Electrode Implantation and EEG
Recording

All experiments were performed under the Animal Care and
Animal Protection Law of the Czech Republic fully compatible
with the guidelines of the European Union directive 2010/63/EU.
The protocol was approved by the Ethics Committee of The Czech
Academy of Sciences (Project License No. 71/2016). Animals were
housed in groups under standard conditions in a room with controlled temperature (22 ± 1°C) and 12/12 h light/dark cycle. Eleven
adult male Wistar rats weighing between 350 and 430 g were used in
this study. The surgical preparation was performed under isoflurane
anesthesia. The animals were implanted with bipolar twisted silver
electrodes (120 µm in diameter, AM Systems, Inc., USA) bilaterally
in the stratum pyramidale (AP: −4.1, L: 2.2, D: 2.5) and stratum
radiatum (AP: −4.6, L: 2.6, D: 2.6) of the dorsal CA1 according to
the stereotaxic atlas (13). The two contacts of each electrode were
0.5 mm apart. Two ground/reference jeweler’s screws were placed
over the cerebellum. Following a 5-day recovery period, animals
were individually video-EEG monitored for 4 weeks continuously.
Spontaneous electrographic activity was amplified, band-pass
filtered (0.1 Hz–1.6 kHz), and digitized at 5 kHz using a RHD2132
32-channel amplifier chip (Intan Technologies, USA). After the
end of the experiment, animals were humanely euthanized by an
overdose of urethane, brains extracted, and processed to verify the
positions of electrodes (Figure 1E).
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FIGURE 1 | The algorithm of sharp-wave ripple (SWR) detection. (A) An
example of the wideband signal containing an SWR event. (B) High-pass
filtered (>100 Hz) signal reveals the ripple oscillation. (C) Root mean square
(RMS) signal computed from the high-pass filtered signal. The line indicates
the detection threshold. The shaded area marks the putative detection.
(D) The autocorrelation function of the shaded segment of the high-pass
filtered signal with detected peaks, which fulfills the criteria for SWR
detection. (E) An example of a Nissl-stained brain slice with electrode tip
located in stratum pyramidale of the CA1 hippocampal subregion.

2

December 2017 | Volume 8 | Article 687

Kudlacek et al.

AEDs and SWRs

Diazepam acted as a positive control since it was shown to
decrease the SWR rate in vivo (14). The interval after each
injection, whether it was an AED or saline, was 3 days to allow
maximal elimination of the drug from the body based on the
known pharmacokinetics (14–16). The doses for levetiracetam
and lacosamide were 80 and 30 mg/kg, respectively. At comparable doses, these drugs were shown to effectively suppress
pHFOs (8, 9). The dose of diazepam was 1 mg/kg which was
shown to reduce or even suppress the SWR rate (14, 17). The
sequence of injections was randomized between animals. In a
given rat, every injection was administered at the same time of
the day (10:30 a.m. or 2:00 p.m.).

Sensitivity and PPV of the detector was 57 and 80%, respectively. Detector’s settings were optimized to achieve mainly high
PPV to detect only true SWRs, omit ambiguous SWRs, and to
minimize the risk of FP detections.

EEG Analysis

Statistical Evaluation

value (PPV) of the detector was calculated using the following
equations:
sensitivity =
PPV =

TP
.
TP + FP

In this study, the primary hypothesis tested was that injections
of selected AEDs do not affect SWR rates. This is in contrast to
the vast majority of drug studies, which examine and test for the
presence of an effect of the drug on specific phenomena, including HFOs. Thus, we had to implement an appropriate statistical
method that tests equality and not an effect. In this study, we
adopted the method recommended by Piaggio et al. (19). For each
rat, each injection and each time after the injection we calculated
average SWR rate during the slow-wave sleep epochs. Then, for
each rat, each drug and each time after the injection, we calculated the ratio of SWR rate after AED injection to SWR rate after
the corresponding saline injection. Since the data did not display
normal distribution, we used a non-parametric approach. For
each drug and each time after the injection, median of the ratios
and its non-parametric confidence interval was calculated. The
non-parametric confidence interval for the median is obtained
as the k-th lowest and the k-th highest value from the sample. k
is determined so that the true population median lies within that
interval with confidence equal or higher than required. In our
study, we required at least 90% confidence. For sample sizes nine
and eight we took k = 2 which gives confidences of 96 and 93%,
respectively. For the three diazepam animals, we took the first
and the last value as the confidence interval (widest possible),
which gives up to 75% confidence (20). We obtained confidence
intervals for all three drugs and two time windows after the injections. These six confidence intervals were compared to equality
margins, which were set to 0.75 and 1.25. If the confidence interval did not cross the equality margins, the AED was considered
to have no effect on SWR rate.
Following equality testing, we performed statistical analysis to
evaluate the possible presence of a statistically significant effect
of AEDs on the SWR rate. In this step, we used the Wilcoxon
signed-rank test on each set of the ratios. Before applying the test,
the ratios were transformed by subtracting 1 so that a decrease in
the SWR rate resulted in a negative number and vice versa. In the
case of a non-significant result, post hoc power of the Wilcoxon
signed-rank test was determined using SD of the data and location shift equal to the equality margin, i.e., 0.25 (21, 22).

EEGs were analyzed using custom made scripts in Matlab 2015a
computing environment (Mathworks Inc., Natick, MA, USA).
Two animals were removed from the analysis due to extremely
noisy EEG signals. In one animal, the experiment was terminated
prematurely due to the loss of the head cap prior to lacosamide
injection. Therefore, the total number of animals used in the
evaluation of the three drugs was nine for levetiracetam, eight
for lacosamide, and three for diazepam. In each animal, SWRs
were analyzed only in the channel in which SWRs displayed the
highest amplitude. Correct positions of these electrodes in the
hippocampal CA1 were verified histologically. We analyzed two
epochs each lasting 2 h. The first epoch was from 0.5 to 2.5 h after
the injection and the second one was from 4.5 to 6.5 h after the
injection. To determine the SWR rate during the same brain state,
we extracted episodes of slow-wave sleep only, from each epoch,
based on the presence of slow waves in the EEG and verified
behaviorally in video recordings.

SWR Detection

Sharp-wave ripples were detected using the modified root mean
square (RMS)-based approach (18). The signal was band-pass
filtered (passband 100–200 Hz) using a FIR filter with a 40-Hz
wide transition band and stopband attenuation at 80 dB. RMS
value was calculated in 4 ms sliding windows. Only segments
of at least 18 ms in duration with an RMS value >1.5 SD above
the RMS mean were selected as putative SWRs. Events closer
than 10 ms were treated as a single event. The next step of the
detection procedure included estimation of the autocorrelation
function in high-pass filtered segments (>100 Hz, otherwise the
same parameters). Detections with at least seven peaks in the
autocorrelation function with a lag corresponding to the SWR
frequency band (100–200 Hz) and with the second peak of at least
25% of magnitude were selected. The main steps of the detection
procedure are visualized in Figures 1A–D.
To evaluate the detector’s performance, 24 randomly selected
epochs of slow-wave sleep were labeled by an expert. Automatic
detections were compared to the expert’s labels. A true positive (TP) detection was defined as the one overlapping with an
expert’s label by at least 50% of the detection’s duration. A false
positive (FP) detection was a detection not fulfilling the criteria
for TP detection. The number of false negatives (FN) was defined
as the number of expert’s labels, which had no overlap with any
of the TP detections. Finally, sensitivity and positive predictive
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TP
TP + FN

RESULTS
In total 43,011 SWRs were detected with 4,779 ± 3,125 events
per animal. The average SWR rate was 16.0 events/min, which
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is congruent with studies focused on SWR in vivo (11, 23–25).
SWR rates of all animals, after each injection, in both analyzed
time windows, are shown in Figure 2. The data revealed the presence of individual variability in the SWR rate and response to the
tested drugs. The crucial parameter for examination of the effect
of an AED is the ratio between the SWR rate after AED injection and the SWR rate after control saline injection (Figure 3).
The median ratio of the SWR rate between levetiracetam and

the control was 0.91 and 0.98 for 30 min and 4.5 h after the
injection, respectively (n = 9 animals). For levetiracetam, the
ratios’ confidence intervals did not cross the equality margins
30 min and 4.5 h after injection (Figure 4). Therefore, SWR rates
after levetiracetam and saline treatment can be considered equal
within the equality margins. The Wilcoxon signed-rank test for
ratios was non-significant for 30 min (p = 0.30) and 4.5 h after the
injection (p = 0.57), with a post hoc power of 88%. For lacosamide,
the median ratio of the SWR rate was 1.14 and 1.22 for each time
epoch (n = 8 animals). The confidence intervals of the SWR rate
ratios crossed the equality margins in both time windows. The
Wilcoxon signed-rank test demonstrated a significant increase in
SWR rate ratio 30 min after injection of lacosamide (p = 0.039).
After 4.5 h the effect of lacosamide was non-significant (Wilcoxon
signed-rank test; p = 0.11; power = 85%). Diazepam, which
was used as a positive control, reduced the SWR rate compared
to the equivalent volume of saline in all rats by >50% with a
median ratio of 0.46 and 0.70 for each time window (Figure 4).
However, statistical significance could not be reached due to the
small number of rats (n = 3 animals; Wilcoxon signed-rank test;
p = 0.25; power = 46%).

DISCUSSION
We have shown that a single dose of levetiracetam and lacosamide does not reduce the rate of SWRs—a representative of
physiological HFOs. The ability to reliably differentiate between
pathological and physiological HFOs represents a crucial step
FIGURE 2 | Sharp-wave ripple (SWR) rates after various treatments. Lines
connect data points from individual animals. LEV, levetiracetam; LCM,
lacosamide; DIA, diazepam; CtrlXXX, injection of equivalent volume of saline;
0.5, half an hour after injection, 4.5, four and half hours after injection.

FIGURE 4 | Medians of ratios of sharp-wave ripple (SWR) rates after drug
injection to rates after corresponding saline injection. Error bars represent
non-parametric confidence intervals of the medians. Dashed line is at value 1
which constitutes no effect. Dotted lines at values 0.75 and 1.25 represent
equality margins. LEV confidence intervals are at 96% confidence and do not
cross the equality margins. LCM significantly increases SWR rate 0.5 h after
administration, but 4.5 h after administration the effect dissipates. Confidence
intervals are 93%. DIA markedly reduces SWR rate 0.5 h after administration
and 4.5 h after administration the effect slowly dissipates. Confidence
intervals are 75%. LEV, levetiracetam; LCM, lacosamide; DIA, diazepam.

FIGURE 3 | Ratios of sharp-wave ripple (SWR) rates after drug treatment to
rates after saline treatment for individual rats. Dashed line is at value 1 which
constitutes no effect. LEV, levetiracetam; LCM, lacosamide; DIA, diazepam;
CtrlXXX, injection of an equivalent volume of saline; 0.5, half an hour after
injection; 4.5, four and half hours after injection.
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toward the clinical utilization of pHFOs as biomarkers of the epileptogenic zone (2, 7). Epileptic pHFOs display a spectral overlap
with physiological HFOs such as SWRs or fast gamma activity.
Fast ripples are considered to be exclusively of epileptic origin,
but physiological activity with a frequency around ~600 Hz has
been described in the neocortex. Matsumoto and colleagues
described features, which discriminated task-related physiological HFOs from pathological ones (26). Pathological HFOs
were characterized by a higher spectral mean, longer duration,
and lower mean frequency. Other studies tried to discriminate
HFOs according to their spatial distribution, relationship with
sleep phases (27), background activity (28), phase relationship
with slow waves (29), or using cognitive tasks (30). However,
the practical implementation of these criteria is challenging.
Experimental treatment with levetiracetam or lacosamide
has been shown to reduce the both ripples and fast ripples in
the pilocarpine model of temporal lobe epilepsy, even though
the effects were region specific (8, 9). In this in vivo study, we
demonstrate that levetiracetam does not decrease the rate of hippocampal SWRs. The confidence intervals were set to tolerate
a 25% change in SWR rate after the treatment. Studies which
explored the effect of levetiracetam and lacosamide on pHFOs
showed that these drugs reduced the pathological ripple rate in
hippocampal structures by an average of 57% for levetiracetam
and by 43% for lacosamide (8, 9). Although we studied the
effect of these AEDs only on specific subtype of physiological
HFOs, these experimental results suggest that the procedure of
pharmacological testing can be a plausible approach to facilitate
discrimination between physiological and pathological HFOs.
Both drugs are used very frequently and their withdrawal and
subsequent introduction is a very common procedure in patients
undergoing invasive explorations. As an alternative, the introduction of AEDs could be replaced by an intravenous application
of levetiracetam at the end of monitoring. HFOs that are not
altered by AEDs can be considered to be physiological HFOs.
The absence of a major effect of the AEDs on the rate of SWRs
and suppression of pHFOs can be explained by the currently
known mechanisms of action of the drugs and cellular mechanisms of HFOs (31, 32). SWRs are oscillations that reflect the
activation of large neuronal ensembles in the hippocampal CA1
region, particularly during sleep. On the cellular level, the oscillation depends on the precise interaction between pyramidal cells
and inhibitory interneurons. The fast inhibitory postsynaptic
potentials on the membrane of principal neurons play a key role
in the coordination of principal cell firing (11). Pyramidal cells
fire heterogeneously during the SWR; some cells can fire during
every successive event, while other cells can fire only occasionally
(17, 33). The sequence of neuronal activity during SWRs replays
the sequence of neuronal activation during behavioral tasks, and
it is considered to represent a mechanism of memory reactivation
and long-term memory formation (12, 34). The cellular dynamics of pHFOs in both ripple and fast ripple bands differs and is
more uniform (31, 32). During each pHFO, a large population
of cells generates a burst of high-frequency action potentials
superimposed on a large depolarizing envelope (35–37). While
high-frequency spiking depends mainly on fast sodium channel
kinetics, the depolarizing envelope is associated with an increase
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in intracellular calcium via the opening of voltage-gated calcium
channels or activation of non-NMDA and NMDA receptors.
Lacosamide modifies voltage-gated sodium channel kinetics
required for fast action potential firing, and it affects only neurons
which are active or depolarized for prolonged periods of time
and thus spares physiological functions (38). Therefore, pathological pHFOs are more susceptible to its effects than SWRs. The
levetiracetam binds to SV2A, which is involved in trafficking
and fusion of synaptic vesicles (39). It seems that levetiracetam
reduces the vesicle release that is important for synaptic
neurotransmission (40). It also partially blocks N-type calcium
channels (41). However, the exact mechanisms of its actions are
not well known, but we can assume that levetiracetam is capable
of interfering with cellular processes involved in intense neuronal
firing and pHFOs.
The absence of the effect of levetiracetam and lacosamide
on the mechanisms of SWRs, in general, can also be deduced
indirectly from the lack of their negative effect on cognitive functions including memory. It is well established that any drug or
procedure, which has the capacity to interfere with the cellular
mechanisms underlying the genesis of SWRs, also has the capacity to induce a memory deficit (42, 43). Levetiracetam is currently
the drug of first choice, and lacosamide has also shown its therapeutic benefits as add-on therapy early after its introduction into
epilepsy therapy. Both drugs are well tolerated by patients and
demonstrate low adverse effects and an absence of a significant
impact on cognition and memory (44–47). From electrophysiological perspective, these observations are supported by our
experimental study, which demonstrates the absence of any suppressive effect of these drugs on the SWR generation. Moreover,
lacosamide was shown to increase the speed of complex visual
information processing (48), which may be in agreement with the
transiently increased SWR rate observed in this study.
A possible limitation of this study is the single-dose scheme
of drug administration. We might have missed the time period
of SWR suppression by the drug. However, based on the known
pharmacokinetics and mechanism of action of these drugs this
seems unlikely (15, 16, 38, 49). Another possibility is that the drug
was cleared from the body before its concentration in the brain
could have reached sufficient intrathecal levels to influence the
SWR rate. However, we used the same dose that was administered
daily in studies exploring the effect of lacosamide and levetiracetam on pHFOs (8, 9) and pharmacokinetic studies showed
that these drugs reach maximal brain concentration within 2 h
after application (15, 16). Another weakness of the study is the
single-dose application. We cannot exclude that prolonged or
chronic application of these drugs may induce long-term changes,
which would affect the properties of SWRs.
In conclusion, we have shown that levetiracetam does not
change the rate of SWRs and lacosamide transiently increases
it. Hence, these drugs can be considered for pharmacological
testing to distinguish physiological versus pHFOs. Levetiracetam
or lacosamide could be introduced toward the end of invasive
exploration, and the response of HFOs to the drug introduction
could be used to determine whether the HFOs are pathological
or physiological. Moreover, our results are congruent with studies
showing no negative effect of these drugs on cognition.
5
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